ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages GRAIL, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – GRAL

Rosen Law Firm is reminding investors who purchased GRAIL, Inc. common stock between May 13, 2025 and February 19, 2026 of an important August 4, 2026 lead plaintiff deadline in an ongoing securities class action. The lawsuit alleges that GRAIL provided overwhelmingly positive statements while concealing material adverse facts about its NHS-Galleri trial, including that the trial period was insufficient to demonstrate the primary endpoint of reducing Stage III-IV cancers.

06/23/2026, 2:00 PM • GlobeNewswire

GRAL Investors Have Opportunity to Lead GRAIL, Inc. Securities Fraud Lawsuit with the Schall Law Firm

The Schall Law Firm is seeking investors who purchased GRAIL, Inc. securities between May 13, 2025 and February 19, 2026 to join a class action lawsuit alleging securities fraud. The company allegedly made false and misleading statements about its NHS-Galleri trial's prospects in reducing Stage III-IV cancers, overstating optimism while concealing adverse trial data.

06/23/2026, 9:58 AM • GlobeNewswire

Bronstein, Gewirtz & Grossman LLC Urges GRAIL, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

A class action lawsuit has been filed against GRAIL, Inc. alleging that company executives made materially false and misleading statements regarding the NHS-Galleri trial's likelihood of success. The complaint claims defendants misrepresented the trial's prospects and concealed adverse data suggesting the three-year timeframe was insufficient to achieve the primary endpoint. Investors who purchased GRAIL securities between May 13, 2025 and February 19, 2026 are encouraged to join the case, with a lead plaintiff deadline of August 4, 2026.

06/22/2026, 12:00 PM • GlobeNewswire

Notice to Long-Term Shareholders of Badger Meter, Inc. (NYSE: BMI); GeneDx Holdings Corp. (NASDAQ: WGS); GRAIL, Inc. (NASDAQ: GRAL); and Verra Mobility Corporation (NASDAQ: VRRM): Grabar Law Office is Investigating Claims on Your Behalf

Grabar Law Office has filed multiple shareholder investigations and securities fraud class actions against Badger Meter, GeneDx Holdings, GRAIL Inc., and Verra Mobility Corporation, alleging that company officers and directors made false or misleading statements about financial performance, business acquisitions, clinical trial results, and contract renewals. All four companies experienced significant stock price declines following disclosure of the alleged misconduct.

06/22/2026, 10:56 AM • GlobeNewswire

A Blood Test That Screens for 50+ Cancers Just Moved Closer to Real-World Use. Here's What It Means for Grail Investors.

Grail's Galleri multi-cancer early detection test missed its primary endpoint in a landmark NHS trial but still has a pathway to FDA approval and insurer coverage. Management points to favorable trends in detecting 12 deadly cancers, upcoming 12-month follow-up data, and strong positive predictive values as reasons for optimism. The stock's future depends on FDA decisions and insurer cost-benefit analyses.

06/21/2026, 6:05 PM • The Motley Fool

GRAL UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Grail (GRAL) Investors of Securities Class Action Lawsuit Deadline on August 4, 2026

Faruqi & Faruqi, LLP is investigating securities fraud claims against Grail, Inc. (NASDAQ: GRAL) for allegedly making false and misleading statements about its NHS-Galleri cancer detection trial. The company touted confidence in the trial's success while concealing that the trial period was insufficient to achieve its primary endpoint. On February 19, 2026, Grail announced the primary endpoint was not observed, causing the stock to plummet 50.55% in a single day from $101.53 to $50.21 per share. Investors who purchased GRAL stock between May 13, 2025 and February 19, 2026 have until August 4, 2026 to seek lead plaintiff status.

06/20/2026, 8:45 AM • GlobeNewswire

GRAL Investors Have Opportunity to Lead GRAIL, Inc. Securities Fraud Lawsuit with the Schall Law Firm

The Schall Law Firm is seeking investors who purchased GRAIL, Inc. securities between May 13, 2025 and February 19, 2026 to join a class action lawsuit alleging securities fraud. The company allegedly made false and misleading statements about its NHS-Galleri trial's prospects in reducing Stage III-IV cancers, concealing adverse data while presenting overly optimistic projections about the three-year study timeline.

06/19/2026, 9:52 AM • GlobeNewswire

Bronstein, Gewirtz & Grossman LLC Urges GRAIL, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

A class action lawsuit has been filed against GRAIL, Inc. alleging that company executives made materially false and misleading statements regarding the NHS-Galleri trial's likelihood of success. The complaint claims defendants misrepresented the trial's prospects and concealed adverse data suggesting the three-year timeframe was insufficient to achieve the primary endpoint. Investors who purchased GRAIL securities between May 13, 2025 and February 19, 2026 are eligible to join the case.

06/18/2026, 12:00 PM • GlobeNewswire

ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Encourages GRAIL, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – GRAL

Rosen Law Firm is reminding investors who purchased GRAIL, Inc. common stock between May 13, 2025 and February 19, 2026 of an important August 4, 2026 lead plaintiff deadline in an ongoing securities class action. The lawsuit alleges that GRAIL provided overwhelmingly positive statements while concealing material adverse facts about its NHS-Galleri trial, including that the trial period was insufficient to demonstrate the primary endpoint of reducing Stage III-IV cancers.

06/16/2026, 7:37 PM • GlobeNewswire

ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages GRAIL, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – GRAL

Rosen Law Firm has filed class action lawsuits on behalf of investors in GRAIL, Inc. and other companies. The GRAIL lawsuit alleges that defendants made materially false and misleading statements regarding the NHS-Galleri trial results, concealing that the trial period was insufficient to demonstrate the primary endpoint of reducing Stage III-IV cancers. Investors who purchased GRAIL stock between May 13, 2025 and February 19, 2026 may be eligible for compensation. The lead plaintiff deadline is August 4, 2026.

06/13/2026, 9:29 PM • GlobeNewswire

DEADLINE ALERT for BMI, PICS, VRRM, and GRAL: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

Class action lawsuits have been filed against four publicly-traded companies alleging materially false and misleading statements. Badger Meter is accused of pulling forward customer orders to conceal weakening demand. PicS failed to disclose credit quality deterioration and reclassified exposures. Verra Mobility concealed dependency on Avis contract extension. Grail misrepresented confidence in trial results. Investors have until August 4, 2026 (or July 27 for BMI) to file lead plaintiff motions.

06/12/2026, 1:24 PM • GlobeNewswire

GRAL Class Action Notice: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Grail, Inc. Class Action Lawsuit

Robbins LLP has filed a class action lawsuit against Grail, Inc. (NASDAQ: GRAL) on behalf of investors who purchased securities between May 13, 2025, and February 19, 2026. The lawsuit alleges that Grail misled investors regarding NHS-Galleri's potential to achieve statistically significant reduction in Stage III-IV cancers. Following the disclosure, Grail's stock price plummeted approximately 50.55% in a single trading day, from $101.53 to $50.21 per share on February 19-20, 2026.

06/11/2026, 1:58 PM • GlobeNewswire

Bronstein, Gewirtz & Grossman LLC Urges GRAIL, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

A class action lawsuit has been filed against GRAIL, Inc. alleging that company executives made materially false and misleading statements regarding the NHS-Galleri trial's likelihood of success. The complaint claims defendants misrepresented the trial's prospects and concealed adverse data suggesting the three-year timeframe was insufficient to achieve the primary endpoint. Investors who purchased GRAIL securities between May 13, 2025 and February 19, 2026 are eligible to join the case, with a lead plaintiff deadline of August 4, 2026.

06/11/2026, 12:00 PM • GlobeNewswire

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages GRAIL, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – GRAL

Rosen Law Firm has filed class action lawsuits on behalf of investors in GRAIL, Inc. (NASDAQ: GRAL) who purchased stock between May 13, 2025 and February 19, 2026. The lawsuit alleges that GRAIL provided misleading statements regarding its NHS-Galleri trial results, concealing material adverse facts about the trial's ability to demonstrate cancer stage reduction. Investors who purchased during the class period may be eligible for compensation. The deadline to serve as lead plaintiff is August 4, 2026.

06/10/2026, 7:44 PM • GlobeNewswire

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Veritone, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - VERI

Rosen Law Firm is encouraging investors who purchased securities of Veritone, Inc. (NASDAQ: VERI) between October 14, 2025 and April 14, 2026 to join a class action lawsuit. The lawsuit alleges that Veritone made false statements regarding its financial reporting, inaccurately recorded revenue and costs, overstated assets, and maintained deficient internal controls, leading to required financial restatements. The firm is also investigating potential securities claims for GRAIL, Inc. and Barclays PLC shareholders.

06/10/2026, 7:44 PM • GlobeNewswire